Loading
A phase 1/2 trial of Lenvatinib, Envafolimab, Sunitinib in non-small-cell lung cancer and small-cell lung cancer, run by 3D Medicines (Sichuan) Co., Ltd., now recruiting.
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors is a phase 1/2 interventional study registered as NCT05024214 by 3D Medicines (Sichuan) Co., Ltd., with 170 participants planned, started 2021-11-15 and due to reach its primary completion in 2026-12. Interventions recorded: Lenvatinib + Envafolimab, Sunitinib. Conditions listed: Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares 3D Medicines, Envafolimab, Lenvatinib, Anti-angiogenic therapy.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares 3D Medicines, Envafolimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Shares Envafolimab, Lenvatinib, Small-molecule kinase inhibitors, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/